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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground/Purpose: Streptococcus agalactiae (GBS), is the most common pathogen causing
infections among perinatal women and neonatal babies. Nonetheless, there are few studies
on the occurrence of GBS among the pregnant women and the mechanisms of GBS resistance
to quinolones and macrolides in Taiwan.
Methods: GBS were isolated from vaginas of the pregnant and non-pregnant symptomatic
women in Taiwan. The prevalence, antimicrobial susceptibility, and mechanisms of resistance
against erythromycin and quinolone of total 188 isolates were studied.
Results: The isolation rate of GBS from pregnant women was significantly higher at 21.8%
compare with the non-pregnant women of 13.2%. Antibiotic susceptibility test of the 188
GBS isolates revealed a high non-susceptible rate for erythromycin (50.0%) while the rate
for levofloxacin was only 4.8%. Among 94 erythromycin non-susceptible GBS isolates, ermB
gene was detected 83.1% (59/71) for those GBS that were non-susceptible to both clindamycin
and tetracycline, which was significantly higher than GBS that are susceptible to clindamycin
but resistant to tetracycline at 43.8% (7/16). No ermA ormef gene was detected in any isolate.
Mutations were detected in the parC and gyrA genes in 14 out of 18 levofloxacin non-suscep-
tible isolates. The predominant mutation type was the combination of Ser79Tyr in parC and
Ser81Leu mutations in gyrA.
Conclusion: GBS is the most common isolated pathogens in vaginal infections in Taiwan, resis-
tance to tetracycline and erythromycin is higher than the rate observed for other regions of
the world, while the resistance rate for levofloxacin was relatively lower in Taiwan.
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Streptococcus agalactiae in Taiwan 511Introduction fully automated bacterial identification and susceptibilityStreptococcus agalactiae, also known as group B strepto-
coccus (GBS), usually resides in the human vagina and/or
intestines. GBS is a predominant group of pathogens that
causes perinatal infections. It has been proven that a high
percentage of neonatal infections due to S. agalactiae
(especially among newborns) occur through vertical trans-
mission from a GBS-colonized mother to the newborn during
labor and birth. Some 5e40% of women carry GBS in their
genital tracts, and 10e30% of pregnant women have tran-
sient vaginal carriage.1e3 GBS also causes bacteremia,
endocarditis, skin and soft-tissue infections, and osteomy-
elitis among patients with compromised immune sys-
tems.4e6 Therefore, maternal intrapartum prophylaxis for
pregnant women colonized with GBS is recommended.
While b-lactam antibiotics are the most commonly used
antibiotics for treatment of GBS infection, the macrolide
antibiotics are selected alternatives for patients with al-
lergies to b-lactam agents or with less severe infections.
Notably, GBS resistance to the macrolides and other anti-
biotics has increased gradually during the past several
years.7,8 In addition, since the first report by Kawamura
et al9 in 2003 on quinolone-resistant GBS, these GBS isolates
have also been identified in the United States, Spain, Brazil,
and several other countries.10e12
Two principal mechanisms are involved in the resistance
of GBS to erythromycin. One mechanism involves the
methylation of the target gene, which is regulated by the
erm gene, whereas the other is the efflux pump mediated
by the mef gene.5 Mutations of the gyrA and parC genes,
which are located in the quinolone resistance-determining
regions (QRDRs), are the main mechanisms for resistance
to quinolones.6,9,12e14 Nonetheless, there are only a few
studies on the occurrence of GBS in pregnant women in
Taiwan as well as on the mechanisms of GBS resistance to
quinolones and macrolides in Taiwan. Therefore, we sur-
veyed the pathogens isolated from pregnant women in
Taiwan during a 1.5-year period to investigate the preva-
lence of GBS and antibiotic susceptibility and resistance of
the isolated GBS strains. Moreover, for the erythromycin-
and quinolone-resistant GBS strains, we investigated the
resistance mechanisms and associated genes in comparison
with isolates from China.Materials and methods
Sources of bacteria
Bacteria were isolated from vaginal swabs from 1088 pa-
tients during the period between January 1, 2011 and May
31, 2012 at the Kuo General Hospital in Tainan, Taiwan. The
patients were 519 asymptomatic pregnant women with
gestation period of 35e37 weeks and 569 nonpregnant but
symptomatic women outpatients with vaginitis who were
treated with drugs recommended by a clinician. Vaginal
secretion was collected using the BBL CultureSwab Plus
Collection and Transport Systems (Becton, Dickinson and
Company, Sparks, MD, USA) following the manufacture’s
instruction. All isolates were identified using the Phoenix 100testing system (Becton, Dickinson and Company). A total of
188 isolates were identified as S. agalactiae. The identities
of these isolates were further confirmed by matrix-assisted
laser desorption/ionization time of flight mass spectrom-
etry (MALDI-TOF MS; Bruker Biotyper, Bremen, German)
analysis. The MALDI-TOF MS analysis produced significantly
quick and reliable results and the species-level identifica-
tion was 100%.15,16 Escherichia coli DH5a was used as a
standard strain for the MALDI-TOF MS analysis.
To reveal and compare the resistance profiles and
possible mechanisms of resistance from among those iso-
lated at the Kuo General Hospital, 30 GBS isolates,
including four erythromycin-susceptible isolates as con-
trols and 26 erythromycin-nonsusceptible isolates, which
had various kinds of minimum inhibitory concentration
(MIC) levels (among them, 9 isolates were quinolone
nonsusceptible), were selected for gene analysis. In
addition, another 30 GBS isolates from the posterior
vaginal fornix secretions of pregnant or healthy nonpreg-
nant women, amniotic fluid of women in delivery, which
had resistance profiles similar to those from the Kuo
General Hospital were provided by the Second Affiliated
Hospital of Zhejiang University, Hangzhou, China. All
participants gave prior informed written consent to
participate in the study.
Drug-susceptibility testing
Antibiotic susceptibility was determined using the Phoenix
100 system (Becton, Dickinson and Company) by the MIC
method, and susceptibility judgment was based on the
criteria set by the Clinical and Laboratory Standards
Institute.17
Determination of efflux pump effects
An efflux mechanism was believed to be present when the
MIC of an agent in the presence of reserpine was at least
fourfold less (2 doubling dilutions) than the MIC in the
absence of reserpine.18 Efflux pump experiments were con-
ducted with the modified broth dilution method of Bast
et al18 for the isolates that showed quinolone or erythro-
mycin resistance but no mutations in QRDR (Isolates 1113,
1319, 1679, 2272) or in the ermA, ermB, and mefA genes
(Isolates S8, S9, S11 from Zhejiang and Isolates 1113, 1319,
2272 from Taiwan). In brief, 100 mL of GBS strains at 1.5 107
colony forming units/mL were inoculated in 2 mL of broth
(with or without 10 mg/mL reserpine) containing different
levels of levofloxacin. After incubation, the MICs of the
strains were determined for levofloxacin or erythromycin
resistance in the absence and presence of reserpine.
Polymerase chain reaction analysis
For the 24 isolates (9 nonsusceptible and 3 susceptible to
levofloxacin from Taiwan and China, respectively) among
the 60 GBS isolates used for comparison, polymerase chain
reaction (PCR) of the relevant genes was conducted to
detect mutations in parC, parE, gyrA, and gyrB for quinolone
resistance. In this study, the gyrA and parC genes were
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Murayama et al,6 whereas amplification of the gyrB and parE
genes was conducted with modified primers based on the
method suggested by Wehbeh et al.12 For the 52 GBS isolates
resistant to erythromycin, the ermA, ermB, andmefA genes
were amplified using primers and conditions previously
described.19,20 PCR amplification was performed using a
TPersonal PCR cycler (Biometra, Go¨ttingen, Germany).
DNA sequencing and analysis
The PCR products of the resistance genes were sequenced
using an ABI 3730 sequencer (Applied Biosystems, Foster
City, CA, USA), and the resulting sequences were compared
with the relevant sequences of S. agalactiae GD201008-001
(accession number: CP003810.1) using DNAMAN software
(Lynnon, Quebec, Canada).
Results
Isolation rate of GBS
Bacteria were isolated from 388 of the 1088 patients. He-
molytic reaction and biochemical identification indicated
that 190 isolates were S. agalactiae. Among them, 114
isolates were from pregnant women and the remaining 76
were from nonpregnant women. Further confirmation
testing using MALDI-TOF MS analysis showed that two of
them (1 isolate each from the pregnant and nonpregnant
groups) were actually Enterococcus faecalis. The isolation
rate of GBS from pregnant women was 113/519 (21.8%) and
that from nonpregnant women was 75/569 (13.2%). There
was a significant difference between the two groups in GBS
isolation rate by Chi-square test (p < 0.01). Overall, 188
(48.4%) isolates were identified to be GBS, forming the
majority, followed by Candida albicans (95; 24.4%), E. coli
(58; 15.0%), Klebsiella pneumoniae (9; 2.4%), and E. fae-
calis (7; 1.8%); in addition, another 31 species (8.0%) were
also identified in this study.
Drug-sensitivity testing
We conducted antibiotic susceptibility testing on all 188
GBS isolates by determining the MICs of nine commonlyTable 1 Susceptibility of the 188 Streptococcus agalactiae isol
Antibiotic Isolates tested Resistanc
Cefepime 188 10 (5.3)
Chloramphenicol 188 13 (6.9)
Clindamycin 188 74 (39.4
Erythromycin 188 92 (48.9
Levofloxacin 188 7 (3.7)
Meropenem 188 2 (1.1)
Penicillin 188 0 (0.0)
Tetracycline 188 162 (86.2
Vancomycin 188 0 (0.0)
a CLSI without an intermediate range.
CLSI Z Clinical and Laboratory Standards Institute.used antibiotics including b-lactam, macrolide, quinolone
agents, and vancomycin. As shown in Table 1, the GBS
strain showed the highest resistance to tetracycline (TE)
with a nonsusceptibility rate close to 87%, followed by
erythromycin and clindamycin (CC), which had non-
susceptibility rates of 50% and 41%, respectively, whereas
only 4.8% of the 188 tested were nonsusceptible to levo-
floxacin. By contrast, the GBS isolates were highly suscep-
tible to cefepime, chloramphenicol, meropenem,
penicillin, and vancomycin. The vast majority of isolates
(n Z 65, 34.6%) were identified as TE nonsusceptible but
susceptible to all other antibiotics; the second type was
nonsusceptible to TE, erythromycin, and CC but susceptible
to all other antibiotics (n Z 48; 25.5%). However, 9.6%
(n Z 18) of isolated strains were susceptible to all antibi-
otics. There was no significant difference between the
pregnant and nonpregnant groups in GBS antibiotic sus-
ceptibility, except for erythromycin (Table 2), as indicated
by Chi-square test (p < 0.01).Drug-sensitivity testing of quinolone- and
macrolide-resistant GBS
To determine the resistance mechanisms and genes
involved in quinolone and erythromycin resistance, we
selected 30 isolates from the Kuo General Hospital,
including nine levofloxacin-nonsusceptible isolates, which
were also nonsusceptible to erythromycin. We also
collected 30 GBS isolates from the Women’s Healthcare
Hospital (Jiaxing, China) and the Second Affiliated Hospital
of Zhejiang University with similar resistance profiles.
Further drug-susceptibility evaluations were conducted for
nine clinically common antibiotics. The results are shown in
Table 3, which indicated that most of the isolates were
highly susceptible to b-lactams. The susceptibility rates for
the GBS isolates from both Taiwan and Zhejiang to peni-
cillin were 100%, whereas the susceptibility rates to cefe-
pime were 86.7% and 93.3%, respectively. Both the isolates
from Taiwan and Zhejiang showed susceptibility rates of
13.3% and 70% to erythromycin and levofloxacin, respec-
tively. Statistical analysis conducted using the Fisher’s
exact probability method indicated that there was no sig-
nificant difference between the samples from the two re-
gions in terms of the resistance profile.ates to nine common antibiotics
e (%) Intermediate (%) Susceptible (%)
da 178 (94.7)
11 (5.9) 164 (87.2)
) 3 (1.6) 111 (59.0)
) 2 (1.1) 94 (50.0)
2 (1.1) 179 (95.2)
da 186 (98.9)
da 188 (100.0)
) 1 (0.5) 25 (13.3)
da 188 (100.0)
Table 2 Analysis of GBS susceptibility of 188 isolates from the pregnant and nonpregnant groups of Taiwan
Antibiotic Pregnant women (n Z 113) Nonpregnant (n Z 75) p
Sa Nonsusceptibleb Sa Nonsusceptibleb
Cefepime 105 8 73 2 0.187
Chloramphenicol 98 15 66 9 0.798
Clindamycin 73 40 38 37 0.057
Erythromycin 64 49 30 45 0.025*
Levofloxacin 109 4 70 5 0.325
Meropenem 112 1 74 1 0.769
Penicillin 113 0 75 0 d
Tetracycline 17 96 8 67 0.387
Vancomycin 113 0 75 0 d
a Susceptible.
b Combined intermediate and resistant.
* p < 0.05, Chi-square test.
GBS Z group B streptococcus.
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genes
No mutations were detected in the QRDRs for the parE and
gyrB genes. The results of the mutation analysis for the parC
and gyrA genes and levofloxacin resistance of the 24 GBS
isolates tested (15 resistant, 3 intermediate, and 6 suscep-
tible) are summarized in Table 4. Sequences were deposited
in theGenBank database and accession numbers for gyrA and
parC were KF285457eKF285459. Among the 15 levofloxacin-
resistant and three intermediate isolates, one intermediate
and 13 resistant isolates were detected to have mutations at
either parC or gyrA. The majority of the isolates with mu-
tations (10 of 14) displayed the same types ofmutations, that
is, Ser79Tyr and Ser81Leu. There were two isolates that had
Ser79Phe and Ser81Leu mutations. In addition, there were
two isolates that had an Ser79Tyr mutation in the parC gene
or an Ser81Leu mutation in the gyrA gene. By contrast, no
mutations were detected in the six levofloxacin-susceptible
isolates. However, nomutationsweredetected from the four
isolates (Isolates 1113, 1319, 1679, and 2272), which were
phenotypically demonstrated to be either resistant or in-
termediate to levofloxacin.Table 3 Analysis of GBS susceptibility of 30 isolates from Taiwan
common antibiotics
Antibiotics Taiwan
Susceptible (%) Nonsusceptible (%) S
Cefepime 26 (86.7) 4 (13.3) 2
Chloramphenicol 21 (70.0) 9 (30.0) 2
Clindamycin 11 (36.7) 19 (63.3)
Erythromycin 4 (13.3) 26 (86.7)
Levofloxacin 21 (70.0) 9 (30.0) 2
Meropenem 28 (93.3) 2 (6.7) 2
Penicillin 30 (100) 0 (0.0) 3
Tetracycline 3 (10.0) 27 (90.0)
Vancomycin 30 (100) 0 (0.0) 3
a Indicates that the data were analyzed using the Fisher’s exact pro
b Indicates that no statistical analysis was conducted.
GBS Z group B streptococcus.Active efflux pump analysis
For the isolates that had quinolone nonsusceptibility but
with no mutations on the QRDRs, the MICs of levofloxacin in
the presence and absence of reserpine were determined.
Similar experiments were also conducted for the six
erythromycin-resistant isolates from which the ermA,
ermB, and mefA genes were not identified. However,
reserpine did not provide greater than a fourfold decrease
in MIC for the tested isolates, indicating that the active
pump mechanism was not functioning (data not shown).Detection and analysis of erythromycin-resistant
genes
From the 26 erythromycin-resistant GBS from Zhejiang, the
ermB gene was detected in six (23.1%) isolates, whereas 14
of the 26 (53.8%) erythromycin-resistant GBS from Taiwan
had the ermB gene (Table 5). Neither the mefA nor ermA
gene was detected in any of these investigated isolates.
Because the 26 erythromycin-resistant GBS from Taiwan did
not have either mefA or ermA, we further examined allwith 30 matched cases from Zhejiang, China to nine clinically
Zhejiang p c2 value
usceptible (%) Nonsusceptible (%)
8 (93.3) 2 (6.7) 0.671 da
4 (80.0) 6 (20.0) 0.371 0.800
8 (26.7) 22 (73.3) 0.405 0.693
4 (13.3) 26 (86.7) 1.000 da
1 (70.0) 9 (30.0) db db
9 (96.7) 1 (3.3) 1.000 da
0 (100) 0 (0.0) db db
5 (16.7) 25 (83.3) 1.000 da
0 (100) 0 (0.0) db db
bability analysis, and use only a p but no c2.
Table 4 Analysis of quinolone-resistance-related
mutations
Sources Serial Code Levofloxacin
resistance
parC
gene
gyrA
gene
Taiwan 1 737 S d d
Taiwan 2 788 S d d
Taiwan 3 934 S d d
Taiwan 4 1113 I d d
Taiwan 5 1192 R Ser79Tyr Ser81Leu
Taiwan 6 1319 R d d
Taiwan 7 1492 R Ser79Tyr Ser81Leu
Taiwan 8 1679 I d d
Taiwan 9 1749 R Ser79Phe Ser81Leu
Taiwan 10 1798 R Ser79Tyr Ser81Leu
Taiwan 11 2272 R d d
Taiwan 12 2280 R Ser79Tyr Ser81Leu
Zhejiang 13 S1 S d d
Zhejiang 14 S3 R Ser79Tyr Ser81Leu
Zhejiang 15 S8 R Ser79Tyr Ser81Leu
Zhejiang 16 S9 R d Ser81Leu
Zhejiang 17 S11 R Ser79Tyr Ser81Leu
Zhejiang 18 S12 S d d
Zhejiang 19 S13 S d d
Zhejiang 20 S15 R Ser79Phe Ser81Leu
Zhejiang 21 S17 I Ser79Tyr Ser81Leu
Zhejiang 22 S22 R Ser79Tyr d
Zhejiang 23 1 R Ser79Tyr Ser81Leu
Zhejiang 24 120411074 R Ser79Tyr Ser81Leu
Leu Z leucine; Phe Z phenylalanine; Ser Z serine;
Tyr Z tyrosine.
Table 5 Comparison the occurrence of ermB gene be-
tween clindamycin (R/S) and tetracycline (R/S) group
among the erythromycin non-susceptible Streptococcus
agalactiae isolates
All isolated from
Taiwan (n Z 94)
Comparison test
Taiwan
(n Z 26)
China
(n Z 26)
ermB
(þ)
ermB
(e)
ermB
(þ)
ermB
(e)
ermB
(þ)
ermB
(e)
CC(R)/TE(R) 59* 12 12 5 6 12
CC(S)/TE(R) 7* 9 2 5 0 5
CC(R)/TE(S) 3 0 0 0 0 3
CC(S)/TE(S) 0 4 0 2 0 0
Total 69 25 14 12 6 20
* p < 0.01, Chi-square test.
CC Z clindamycin; R Z resistant (included intermediate);
S Z susceptible; TE Z tetracycline.
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mefA and ermA and obtained the same results. However, in
the 94 erythromycin-nonsusceptible GBS strains obtained in
this study, the ermB gene was detected in 69 isolates
(73.4%), suggesting that the most predominant resistant
mechanism may be due to the ermB gene product. For
antibiotic patterns (1) erythromycin combined with CC and
TE-resistant GBS, (2) CC susceptible but TE resistant, (3) CC
resistant but TE susceptible, and (4) susceptible to both CC
and TE, the ermB gene carried rate was 83.1% (59/71),
43.8% (7/16), 100% (3/3), and 0% (0/4), respectively (Table
5). There was a significant difference between the two
groups [CC(R)/TE(R) vs. CC(S)/TE(R)] in terms of GBS non-
susceptibility to erythromycin and the ermB gene carried
rate by Chi-square test (p < 0.01; Table 5). Although the
rate of erythromycin nonsusceptibility for the GBS strains
isolated from nonpregnant women was higher than the
pregnant group (45/75 and 49/113, respectively), there was
no difference in the occurrence of the ermB gene (33/45
and 36/49, respectively; p Z 0.99).Discussion
GBS is the most common pathogen that causes infections in
perinatal women and neonatal babies. In the United States
and Europe, neonatal bacteremia, pneumonia, and men-
ingitis due to GBS infections lead to a mortality rate as highas 4e6%. GBS also causes skin and soft-tissue infection,
urinary bladder infection, bacteremia, pneumonia, endo-
carditis, and osteomyelitis in adults, especially in patients
with diabetes and cancer.4,21 However, little attention has
been paid to GBS infections in pregnant women in Taiwan.
We found that GBS accounted for almost half (48.4%) of
the colonizing and clinical strains isolated from the vaginal
tracts of women. This rate is much higher than that of C.
albicans, which has been considered the commonest caus-
ative pathogen of vaginal infection. Our findings indicate
the importance of monitoring GBS, especially in pregnant
women.
GBS is reportedly highly resistant to erythromycin, TE,
and CC.7,22e24 We found that the nonsusceptibility rates for
erythromycin, TE, and CC among the GBS isolates in Taiwan
ranged from 41% to 87%. The resistance rate for TE was as
high as 86.2%, which was almost as high as the reported rate
(97.3%) in Tunisia,22 slightly higher than the reported rate
of 81.5% in China,23 and much higher than the reported rate
(46.5%) in Japan.24 The nonsusceptibility rate for erythro-
mycin was approximately 50%, which is close to the re-
ported rate (50.7%) in the USA,7 but greater than the rate
reported in Tunisia (40.0%),22 and less than the rate in
China (71.2%),23 indicating that the resistance of GBS to the
macrolides in Taiwan is as critical as in the other regions of
the world. By contrast, penicillin and cefepime showed high
sensitivity, which is in accordance with other re-
ports,20,22,24 suggesting that penicillin is still among the
best treatment choices for GBS infections.
PCR amplification and DNA sequencing of the 52
erythromycin-resistant GBS isolates (26 isolates each from
Taiwan and China for comparison test) revealed that 20
(38.5%) carried the ermB gene (Table 5), and the sequence
was highly similar to that of GenBank Accession number
EF422360.1, which was isolated from cattle in Taiwan.
Neither mefA nor ermA was detected from the isolates.
This finding is in line with the study by Betriu et al,25 in
showing that ermB is the main mechanism of erythromycin
resistance in GBS. However, none of these three genes
were detected in 20 of the 26 isolates from Zhejiang nor in
12 of the 26 isolates from Taiwan that were resistant to
Streptococcus agalactiae in Taiwan 515erythromycin. Remarkably, all the 94 erythromycin-
resistant isolates we collected in this study at the Kuo
General Hospital showed the ermB gene carried rate of
73.4%, which is higher than the rate mentioned based on a
previous comparison test with 26 isolates (53.8%). This
may be because the comparison test selects more
erythromycin-resistant but CC-susceptible strains (9/26 vs.
20/94).
In this study, 73.4% of the isolates carried the ermB gene
of the total GBS erythromycin-nonsusceptible strains, and
the rate is significantly higher than that reported in USA and
Spain (13.0% and 58.1%, respectively)4,5; however, our rate
is close to that reported in Japan (87%) by Murayama et al.6
In addition, the ermA, ermB, or mefA genes were not
detected in 26.6% of the isolates. Dogan et al4 reported the
types of GBS that were unable to detect any of the
erythromycin-resistant determinants examined (ermA,
ermB, and mefA), and were highly resistant to erythro-
mycin but susceptible to CC. As indicated in Table 5, in our
comparison test, five isolates from Taiwan and China each
showed results similar to that reported by Dogan et al4;
nevertheless, the ermB gene was detected in two strains. In
the 94 erythromycin-nonsusceptible GBS isolates surveyed
for ermA, ermB, and mefA, 69 had the ermB gene but not
ermA and mefA. Among them, 16 isolates were erythro-
mycin resistant but susceptible to CC and TE, seven carried
the ermB gene, and nine did not (Table 5). Although not
currently reported in S. agalactiae, single-nucleotide
changes in 23S ribosomal ribonucleic acid or in ribosomal
proteins conferring macrolide resistance have been re-
ported for many bacteria, including Streptococcus pneu-
moniae.26,27 It is thus possible that a ribosomal mutation is
responsible for the resistance in this specific isolate. This
result implies that there might be additional mechanisms
that are involved with erythromycin resistance, which
merits further investigation.
Only 4.8% of the total GBS isolates were levofloxacin
nonsusceptible. This rate is significantly lower than that
reported in China (37.7% resistance),23 and is even lower
than that reported in Japan (18.4% resistance), as reported
by Ueno et al.24 Quinolones are not normally used in China
for treating GBS infections in pregnant women and new-
borns. However, because quinolones are widely used in
China for both clinical and agricultural purposes as well as
in animal feedings, continuous and wide use of quinolones
could have elevated the resistance of various pathogens
including GBS to the quinolones. Research28 indicated that
there is a high rate of bacteria in the environment that
carries quinolone-resistant genes, which might be relevant
to the high resistance to quinolones. In addition to plasmid-
mediated quinolone-resistant genes, there are other
mechanisms such as the mutations in Subunits A and B of
the DNA topoisomerases (gyrA, gyrB, parC, and parE ) that
are also involved in the high resistance against quinolones.
No mutations were detected in the QRDRs of the gyrB and
parE genes, which is similar to reports of other studies
indicating that mutations for quinolone resistance among
the GBS isolates are mainly due to the mutations of the
parC and gyrA genes. The main mutation pattern observed
was Ser79Phe and Ser79Tyr in the parC gene and Ser81Leu
in the gyrA gene.6,9,12 There are a few reports in Taiwan
and China for such data. In our current study, we detectedmutations from 14 of the 18 levofloxacin-nonsusceptible
isolates; the mutation patterns of Ser79Tyr in parC and
Ser81Leu in gyrA were the most frequent, followed by
Ser79Phe in parC and Ser81Leu in gyrA.
Although the resistance pattern of the 30 selected
quinolone- and/or macrolide-resistant GBS from Taiwan
had highly similar resistant profiles to those from China,
the gene analysis indicated that the ermB-positive rate
(53.8%, 14/26) for GBS from Taiwan was much higher than
that of the isolates from China (23.1, 6/26). Among the 18
levofloxacin-nonsusceptible GBS isolates, nine were from
Taiwan and nine were from China. Although the mutation
patterns in the parC and gyrA genes from both Taiwan and
China were dominated by the Ser79Tyr and Ser81Leu
patterns, other mutations were also detected in the iso-
lates from China: six isolates had the predominant
Ser79Tyr and Ser81Leu mutations, one had Ser79Phe and
Ser81Leu mutations, one had only the Ser79Tyr mutation,
and one had only the Ser81Leu mutation. By contrast, only
four of nine isolates in Taiwan had the Ser79Tyr and
Ser81Leu mutations and one had the Ser79Phe and
Ser81Leu mutations. No mutations were detected in the
parC and gyrA genes from the four nonsusceptible isolates
in Taiwan, which is similar to the results of Ki et al,14
although these test strains were intermediate resistant
to levofloxacin (Table 4). Detection of the active efflux
pump using reserpine as the inhibitor was unable to
identify any isolates that demonstrated a greater than
fourfold decrease in the MIC, indicating that the reserpine
inhibiting efflux pump is not functioning in those isolates.
Other mechanisms, including plasmid-encoded quinolone
resistance, have been reported for Gram-negative organ-
isms,29 but their association with quinolone resistance in
Gram-positive organisms has not been demonstrated.30
Mutations outside the QRDRs may also contribute to the
expression of resistance in streptococci. In a laboratory-
generated quinolone-resistant strain, mutations in the
promoter region of the parE gene(s) decreased transcript
levels of parC and increased ciprofloxacin resistance even
when no mutations were present in the QRDR.31
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